Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: A single-institution phase III trial

Endocrine-Related Cancer

Volumn 12, Issue 2, 2005, Pages 383-392

  Bottini, A ^b   Berruti, A ^b   Brizzi, M P ^b   Bersiga, A ^b   Generali, D ^b   Allevi, G ^b   Aguggini, S ^b   Bolsi, G ^b   Bonardi, S ^b   Tondelli, B ^b   Vana, F ^b   Tampellini, M ^b   Alquati, P ^b   Dogliotti, Luigi ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; TAMOXIFEN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FEVER; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MAJOR CLINICAL STUDY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR SHRINKAGE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EPIRUBICIN; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; TAMOXIFEN;

EID: 21244497296     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00945     Document Type: Article

References (29)

1. Albain KS, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Schneider DJ, Abeloff MD, Norton L et al. 2002 Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proceedings of American Society of Clinical Oncology 21 abstract 143.
2. Amadori D, Volpi A, Maltoni R, Nanni O, Amaducci L, Amadori A, Giunchi DC, Vio A, Saragoni A & Silvestrini R 1997 Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Research and Treatment 43 7-14.
3. Berman E, Adams M, Duigou-Ostendorf R, Godfrey L, Clarkson B & Andreeff M 1991 Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 77 818-825.
4. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R & Rilke F 1990 Primary chemotherapy to avoid mastectomy in tumours with diameters of three centimetres or more. Journal of National Cancer Institute 82 1539-1545.
5. Bonetti A, Zaninelli M, Rodella S, Molino A, Sperotto L, Piubello Q, Bonetti F, Nortilli R, Turazza M & Getto GL 1996 Tumor proliferative activity and response to first line chemotherapy in advanced breast cancer. Breast Cancer Research and Treatment 38 289-297.
6. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Di Marco B, Cirillo F, Tampellini M, Bolsi G, Aguggini S et al. 1998 Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients. International Journal of Oncology 13 385-390.
7. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, DiMarco B, Aguggini S, Bolsi G, Cirillo F et al. 2000 p53 but not bcl2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clinical Cancer Research 6 2751-2758.
8. Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, Brunelli A, Bolsi G, Allevi G, Generali D et al. 2001 Relationship between tumor shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. British Journal of Cancer 85 1106-1112.
9. Campiglio M, Somenzi G, Olgiati C, Beretta G, Balsari A, Zaffaroni N, Valagussa P & Menard S 2003 Role of proliferation in HER2 status predicted response to doxorubicin. International Journal of Cancer 105 568-573.
10. Clarke RB, Laidlaw IJ, Jones LJ, Howell A & Anderson E 1993 Effect of tamoxifen on Ki67 labelling index in human breast tumors and its relationship to estrogen and progesterone receptor status. British Journal of Cancer 67 606-611.
11. Cleator S, Parton M & Dowsett M 2002 The biology of neoadjuvant chemotherapy for breast cancer. Endocrine-related Cancer 3 183-195.
12. Colleoni M, Orvieto E, Nole F, Orlando L, Minchella I, Viale G, Peruzzotti G, Robertson C, Noberasco C, Galimberti V et al. 1999 Prediction of response to primary chemotherapy for operable breast cancer. European Journal of Cancer 35 574-579.
13. Daidone MG, Silvestrini R, Valentinis B, Ferrari L & Bartoli C 1991 Changes in cell kinetics induced by primary chemotherapy in breast cancer. International Journal of Cancer 47 380-383.
14. Daidone M, Veneroni S, Benini E, Tomasic G, Coradini D, Mastore M, Brambilla C, Ferrari L & Silvestrini R 1999 Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. International Journal of Cancer 84 580-586.
15. Dogliotti L, Berruti A, Buniva T, Zola P, Bau MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F et al. 1996 Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: Results from a multicenter prospective randomized trial. Journal of Clinical Oncology 14 1165-1172.
16. Early Breast Cancer Trialists' Collaborative Group 1998a Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352 930-942.
17. Early Breast Cancer Trialists' Collaborative Group 1998b Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351 1451-1467.
18. Elston CW & Ellis IO 1991 Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer; experience from a large study with long-term follow-up. Histopathology 19 403-410.
19. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology 16 2672-2685.
20. Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S et al. 2001 Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. Journal of Clinical Oncology 19 931-942.
21. Fossati R, Confalonieri C, Torri W, Ghislandi E, Penna A, Pistotti V, Tinazzi A & Liberati A 1998 Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31.510 women. Journal of Clinical Oncology 16 3439-3460.
22. Goldirsch A, Colleoni M & Gelber RD 2002 Endocrine therapy of breast cancer. Annals of Oncology 13 61-68.
23. Greensberg DA, Carpenter CL & Messing RO 1987 Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC 12 neurosecretory cell line. Cancer Research 47 70-76.
24. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I & Coindre JM 1996 Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB2, MIB1, pS2 and GST. British Journal of Cancer 74 1458-1465.
25. McCarty KS Jr, Miller LS, Cox EB, Konrath J & McCarty KS Sr 1985 Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Archives of Pathology and Laboratory Medicine 109 716-721.
26. Osborne CK, Kitten L & Arteaga CL 1989 Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. Journal of Clinical Oncology 6 710-717.
27. Pico C, Martin M, Jara C, Barnadas A, Pelegri A, Balil A, Camps C, Frau A, Rodriguez-Lescure A, Lopez-Vega JM et al.; GEICAM Group 2004 Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9001 study. Annals of Oncology 15 79-87.
28. Sledge GW Jr, Hu P, Falkson G, Tormey D & Abeloff M 2000 Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: an Eastern cooperative Oncology Group Study. Journal of Clinical Oncology 18 262-266.
29. World Health Organization 1978 WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication. Geneva: UICC.